Overview

A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants

Status:
COMPLETED
Trial end date:
2024-12-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess potential effects of enpatoran on cardiac repolarization (i.e. prolongation of QT interval).
Phase:
PHASE1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Collaborator:
Merck KGaA, Darmstadt, Germany
Treatments:
Moxifloxacin